108 related articles for article (PubMed ID: 10222355)
21. Increased urinary excretion of collagen metabolites in cadmium-metallothionein nephropathy.
Sato M; Sasaki M; Nagai Y
Arch Toxicol; 1987 Dec; 61(2):116-9. PubMed ID: 3439883
[TBL] [Abstract][Full Text] [Related]
22. Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis.
Kawana K; Takahashi M; Hoshino H; Kushida K
Clin Chim Acta; 2002 Feb; 316(1-2):109-15. PubMed ID: 11750280
[TBL] [Abstract][Full Text] [Related]
23. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview.
Simsek B; Karacaer O; Karaca I
Chin Med J (Engl); 2004 Feb; 117(2):291-5. PubMed ID: 14975218
[TBL] [Abstract][Full Text] [Related]
24. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
25. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
Clemens JD; Herrick MV; Singer FR; Eyre DR
Clin Chem; 1997 Nov; 43(11):2058-63. PubMed ID: 9365389
[TBL] [Abstract][Full Text] [Related]
26. Urinary galactosyl-hydroxylysine in postmenopausal osteoporotic women: A potential marker of bone fragility.
Lo Cascio V; Bertoldo F; Gambaro G; Gasperi E; Furlan F; Colapietro F; Lo Cascio C; Campagnola M
J Bone Miner Res; 1999 Aug; 14(8):1420-4. PubMed ID: 10457275
[TBL] [Abstract][Full Text] [Related]
27. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
28. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
29. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
30. Urinary excretion of hydroxyproline and hydroxylysyl glycosides in adjuvant-induced arthritis.
Orloff S; Rao VH; Verbruggen L
Ital J Biochem; 1979; 28(3):173-82. PubMed ID: 553901
[TBL] [Abstract][Full Text] [Related]
31. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
[TBL] [Abstract][Full Text] [Related]
33. Toxicological effects of an organophosphorus pesticide (dimethoate) on urinary collagen metabolites in normal and high protein diets fed female albino rats.
Reddy PN; Raj GD; Dhar SC
Life Sci; 1991; 49(18):1309-18. PubMed ID: 1921647
[TBL] [Abstract][Full Text] [Related]
34. Markers of bone turnover: biochemical and clinical perspectives.
Pagani F; Francucci CM; Moro L
J Endocrinol Invest; 2005; 28(10 Suppl):8-13. PubMed ID: 16550716
[TBL] [Abstract][Full Text] [Related]
35. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
36. Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Hamano T; Fujii N; Nagasawa Y; Isaka Y; Moriyama T; Okada N; Imai E; Horio M; Ito T
Bone; 2006 Nov; 39(5):1067-1072. PubMed ID: 16781904
[TBL] [Abstract][Full Text] [Related]
37. The first synthesis of glucosylgalactosyl hydroxylysine (Glu-Gal-Hyl), an important biological indicator of collagen turnover.
Allevi P; Anastasia M; Paroni R; Ragusa A
Bioorg Med Chem Lett; 2004 Jun; 14(12):3319-21. PubMed ID: 15149698
[TBL] [Abstract][Full Text] [Related]
38. Development of an immunoassay for urinary galactosylhydroxylysine.
Leigh SD; Ju HS; Lundgard R; Daniloff GY; Liu V
J Immunol Methods; 1998 Nov; 220(1-2):169-78. PubMed ID: 9839938
[TBL] [Abstract][Full Text] [Related]
39. Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover.
Beardsworth LJ; Eyre DR; Dickson IR
J Bone Miner Res; 1990 Jul; 5(7):671-6. PubMed ID: 2118710
[TBL] [Abstract][Full Text] [Related]
40. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
